AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18512087 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 18512087 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 40
Study 16614585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of douching for 8 weeks
Number of subjects: 48
Study 16614585 — intervention group
Group type: COMPARATOR
Intervention: Continuation of douching
Number of subjects: 48
Study 16614585 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of vaginal flora between groups
Number of subjects: 48
Study 14649610 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone (Group A: 1 mg/kg)
Number of subjects: 20
Study 14649610 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus meperidine (Group B: 0.5 and 1 mg/kg)
Number of subjects: 20
Study 10879380 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 40
Study 10879380 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 40
Study 8774204 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intravenous heparin protocol
Number of subjects: 199
Study 30318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib, Nilotinib, or Ponatinib (frontline TKI therapy)
Number of subjects: 219
Study 27378231 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin pessary
Number of subjects: 700
Study 27378231 — intervention group
Group type: COMPARATOR
Intervention: Standard Arm (control)
Number of subjects: 700
Study 23407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 gm)
Number of subjects: 137
Study 23407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexketoprofen (50 mg)
Number of subjects: 137
Study 23407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 137
Study 23035005 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 39
Study 23035005 — intervention group
Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 39
Study 21992890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent neuromuscular electrical stimulation applied to the right quadriceps muscle for 30 minutes daily.
Number of subjects: 0
Study 21992890 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-stimulated limb).
Number of subjects: 0
Study 18028530 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 180
Study 18028530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16144892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 8 g/d
Number of subjects: 39
Study 16144892 — intervention group
Group type: COMPARATOR
Intervention: Metformin, 2 g/d
Number of subjects: 39
Study 12696778 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive tibial nerve stimulation (Group I)
Number of subjects: 28
Study 12696778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxybutynin 5 mg t.i.d. (Group II)
Number of subjects: 28
Study 12696778 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group III)
Number of subjects: 28
Study 9894548 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) used daily for 3 or 6 months
Number of subjects: 204
Study 9894548 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 204
Study 9894548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 204
Study 7570436 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management programme based on home peak flow monitoring and surgery review by a general practitioner or practice nurse
Number of subjects: 72
Study 7570436 — intervention group
Group type: COMPARATOR
Intervention: Planned visits for surgery review only
Number of subjects: 72
Study 2197335 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Number of subjects: 106
Study 2197335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Number of subjects: 106
Study 2197335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 7423160 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily doses of 220 mg zinc sulfate (group B)
Number of subjects: 91
Study 7423160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 91
Study 7423160 — intervention group
Group type: COMPARATOR
Intervention: No zinc therapy (group A)
Number of subjects: 91
Study 7423160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc substitution in low zinc group B
Number of subjects: 91
Study 7423160 — intervention group
Group type: COMPARATOR
Intervention: Initial ulcer areas in patients with higher serum zinc levels (group A)
Number of subjects: 91
Study 31569307 — intervention group
Group type: EXPERIMENTAL
Intervention: Future-oriented message with gain framing
Number of subjects: 195
Study 31569307 — intervention group
Group type: EXPERIMENTAL
Intervention: Future-oriented message with loss framing
Number of subjects: 195
Study 31569307 — intervention group
Group type: COMPARATOR
Intervention: Present-oriented message with gain framing
Number of subjects: 195
Study 31569307 — intervention group
Group type: COMPARATOR
Intervention: Present-oriented message with loss framing
Number of subjects: 195
Study 30819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + radiation therapy + temozolomide
Number of subjects: 116
Study 30819765 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy + temozolomide
Number of subjects: 116
Study 30819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal imaging (diffusion, perfusion, spectroscopy)
Number of subjects: 116
Study 30819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal imaging
Number of subjects: 116
Study 28039050 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG administration (250 IU intramuscularly 3 times per week for 4 weeks)
Number of subjects: 30
Study 28039050 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG administration
Number of subjects: 30
Study 26390998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based program (Healthy Heart Profile)
Number of subjects: 160
Study 23566033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose (group A)
Number of subjects: 158
Study 23566033 — intervention group
Group type: COMPARATOR
Intervention: Wrapping (group B)
Number of subjects: 158
Study 23566033 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance variations
Number of subjects: 158
Study 21392619 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 124
Study 21392619 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (MED)
Number of subjects: 124
Study 19479161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango
Number of subjects: 58
Study 19479161 — intervention group
Group type: EXPERIMENTAL
Intervention: Waltz/Foxtrot
Number of subjects: 58
Study 19479161 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 58
Study 17090165 — intervention group
Group type: EXPERIMENTAL
Intervention: Laceback ligatures
Number of subjects: 15
Study 17090165 — intervention group
Group type: COMPARATOR
Intervention: Superelastic NiTi closed coil springs
Number of subjects: 15
Study 14687015 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) 200 U
Number of subjects: 60
Study 14687015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14687015 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) twice injected
Number of subjects: 60
Study 11378317 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 144
Study 11378317 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 144
Study 9226739 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg idazoxan
Number of subjects: 15
Study 9226739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7516372 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 1600
Study 7516372 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1600
Study 7516372 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (both dosages)
Number of subjects: 1600
Study 7516372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1600
Study 3317958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's iodine, 0.3 ml thrice daily for 9 days
Number of subjects: 12
Study 3317958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31654634 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Franseen needle
Number of subjects: 110
Study 31654634 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge forward-bevel needle
Number of subjects: 110
Study 29542111 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based community paramedicine program (EPIC)
Number of subjects: 30
Study 28622956 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month physical activity intervention
Number of subjects: 154
Study 28622956 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control condition
Number of subjects: 154
Study 28622956 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month physical activity intervention (obese participants)
Number of subjects: 154
Study 26652073 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion Program (HPP)
Number of subjects: 80
Study 26652073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 24016490 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily in addition to standard medical therapy
Number of subjects: 7228
Study 24016490 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily in addition to standard medical therapy
Number of subjects: 7228
Study 24016490 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily
Number of subjects: 7228
Study 24016490 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 7228
Study 21980798 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sublingual immunotherapy (SLITOne, ALK) for two consecutive pollen seasons
Number of subjects: 162
Study 18506425 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study 15626611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectronic sniffers incorporating alcohol oxidase (AOD) for measuring ethanol vapor
Number of subjects: 0
Study 15626611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectronic sniffers incorporating aldehyde dehydrogenase (ALDH) for measuring acetaldehyde
Number of subjects: 0
Study 12147928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-reported blood pressures
Number of subjects: 49
Study 10356376 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical acupuncture
Number of subjects: 29
Study 10356376 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 29
Study 7626592 — intervention group
Group type: COMPARATOR
Intervention: Psyllium and psyllium-citrus pectin mixture (2.2 g)
Number of subjects: 28
Study 7626592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-beet fibre (6 g)
Number of subjects: 28
Study 1782972 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 75 micrograms/h (Fentanyl‐TTS)
Number of subjects: 50
Study 1782972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7075190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Sulprostone at 4 hourly intervals for 8 doses
Number of subjects: 56
Study 7075190 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg Sulprostone at 8-hour intervals for 4 doses
Number of subjects: 56
Study 7075190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone (both doses)
Number of subjects: 56
Study 31058986 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray 1
Number of subjects: 24
Study 31058986 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray 2
Number of subjects: 24
Study 31058986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion
Number of subjects: 24
Study 31058986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 24
Study 31694576 — intervention group
Group type: EXPERIMENTAL
Intervention: INH/100 (8% sevoflurane in 100% oxygen)
Number of subjects: 200
Study 31694576 — intervention group
Group type: EXPERIMENTAL
Intervention: INH/50 (8% sevoflurane in 50% oxygen and 50% nitrous oxide)
Number of subjects: 200
Study 31694576 — intervention group
Group type: EXPERIMENTAL
Intervention: Phnl/PROP (2.2 mg/kg propofol preceded by 160 mcg phenylephrine)
Number of subjects: 200
Study 31694576 — intervention group
Group type: COMPARATOR
Intervention: PROP (2.2 mg/kg propofol)
Number of subjects: 200
Study 31694576 — intervention group
Group type: EXPERIMENTAL
Intervention: INH/100, INH/50, Phnl/PROP (combined)
Number of subjects: 200
Study 28391968 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical victimization
Number of subjects: 11110
Study 28391968 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational victimization
Number of subjects: 11110
Study 28391968 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal victimization
Number of subjects: 11110
Study 28391968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low peer support
Number of subjects: 11110
Study 25968340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 71
Study 25968340 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral propranolol)
Number of subjects: 71
Study 23482590 — intervention group
Group type: EXPERIMENTAL
Intervention: AG (1, 3, and 5 μg/kg per h) infused over 65 min
Number of subjects: 22
Study 23482590 — intervention group
Group type: EXPERIMENTAL
Intervention: AG (1 μg/kg per h) infused over 210 min
Number of subjects: 22
Study 23482590 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG (4 μg/kg per h) infused over 210 min
Number of subjects: 22
Study 23482590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AG and DAG infused over 210 min
Number of subjects: 22
Study 23482590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration
Number of subjects: 22
Study 21715189 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair (PR)
Number of subjects: 72
Study 21715189 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS buttressed repair
Number of subjects: 72
Study 19194213 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I
Number of subjects: 460
Study 19194213 — intervention group
Group type: COMPARATOR
Intervention: ATD
Number of subjects: 460
Study 17011324 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 398
Study 17011324 — intervention group
Group type: COMPARATOR
Intervention: Standardized approach without swaddling
Number of subjects: 398
Study 15335127 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care model for depression implemented in practices
Number of subjects: 180
Study 15335127 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care model for depression
Number of subjects: 180
Study 15335127 — intervention group
Group type: EXPERIMENTAL
Intervention: Change strategy supporting practice change
Number of subjects: 180
Study 11352778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (125 ml, tds) co-administered with indomethacin (50 mg, tds)
Number of subjects: 22
Study 11352778 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg, tds) with whey protein (control)
Number of subjects: 22
Study 11352778 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostral solutions (125 ml, tds)
Number of subjects: 22
Study 11352778 — intervention group
Group type: COMPARATOR
Intervention: Control solutions (125 ml, tds)
Number of subjects: 22
Study 9209895 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (MTC) intravenous bolus after a 2-h saline infusion
Number of subjects: 39
Study 9209895 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h dopamine infusion at 0.01 microgram/kg/min with a 10 mg intravenous bolus of MTC given at the second hour of dopamine infusion
Number of subjects: 39
Study 9209895 — intervention group
Group type: COMPARATOR
Intervention: 4-h saline infusion
Number of subjects: 39
Study 8352298 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 42
Study 8352298 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study 3610737 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 0.5 mg norethindrone
Number of subjects: 55
Study 3610737 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms mestranol and 1.0 mg norethindrone
Number of subjects: 55
Study 28296201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lixisenatide and basal insulin (LIX group)
Number of subjects: 31
Study 28296201 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injection therapy (MDI group)
Number of subjects: 31
Study 27496696 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (Movement Coaching)
Number of subjects: 412
Study 27496696 — intervention group
Group type: COMPARATOR
Intervention: Low intensity intervention
Number of subjects: 412
Study 24468198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 376
Study 24468198 — intervention group
Group type: COMPARATOR
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 376
Study 24468198 — intervention group
Group type: COMPARATOR
Intervention: Combined PDA and CDSMP (COM)
Number of subjects: 376
Study 24468198 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 376
Study 23714399 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + Reduced tacrolimus (TAC)
Number of subjects: 245
Study 23714399 — intervention group
Group type: COMPARATOR
Intervention: TAC Control
Number of subjects: 245
Study 23714399 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + Reduced TAC
Number of subjects: 245
Study 21071167 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video (Living Proof)
Number of subjects: 489
Study 21071167 — intervention group
Group type: COMPARATOR
Intervention: Informational video (Facts for Life)
Number of subjects: 489
Study 18411832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 24
Study 18411832 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 24
Study 16607077 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 0
Study 16607077 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study 15052977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 70
Study 15052977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 70
Study 15052977 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 70
Study 15052977 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 70
Study 11025358 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sham Feeding (MSF)
Number of subjects: 8
Study 11025358 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Number of subjects: 8
Study 11025358 — intervention group
Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 8
Study 8851899 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% of isometric maximal voluntary contraction (MVC) at 40 degrees/second
Number of subjects: 7
Study 8851899 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of isometric maximal voluntary contraction (MVC) at 40 degrees/second
Number of subjects: 7
Study 8851899 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% of isometric maximal voluntary contraction (MVC) at 80 degrees/second
Number of subjects: 7
Study 8851899 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of isometric maximal voluntary contraction (MVC) at 80 degrees/second
Number of subjects: 7
Study 8851899 — intervention group
Group type: COMPARATOR
Intervention: Contraction velocity (40 vs 80 degrees/second)
Number of subjects: 7
Study 8851899 — intervention group
Group type: COMPARATOR
Intervention: Force decrement during the test-contraction
Number of subjects: 7
Study 8851899 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude during counter movement at high forces and high velocities
Number of subjects: 7
Study 8851899 — intervention group
Group type: COMPARATOR
Intervention: Frequency content of EMG signals during dynamic contractions and postexercise test-contraction
Number of subjects: 7
Study 1933162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline sclerotherapy
Number of subjects: 92
Study 1933162 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 92
Study 1933162 — intervention group
Group type: COMPARATOR
Intervention: Aspiration
Number of subjects: 92
Study 93043 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide (400 or 600 mg every eight hours)
Number of subjects: 12
Study 31950776 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct management by intensivists without residents
Number of subjects: 314
Study 31950776 — intervention group
Group type: COMPARATOR
Intervention: Resident management under high-intensity intensivist staffing
Number of subjects: 314
Study 29695175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 66
Study 29695175 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 66
Study 28487139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramped position (head of the bed elevated to 25°)
Number of subjects: 260
Study 28487139 — intervention group
Group type: COMPARATOR
Intervention: Sniffing position (torso supine, neck flexed, and head extended)
Number of subjects: 260